SCHEMBL14770668

SCHEMBL14770668

c1ccc2c(c1)oc1ccc(-c3cc(-c4cncc(-c5ccc6oc7ccc(-n8c9ccccc9c9ccccc98)cc7c6c5)c4)cc(-n4c5ccccc5c5ccccc54)c3)cc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 2/20 0.35
MAPT P10636 2/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
CHEK2 O96017 1/20 0.34
PDE10A Q9Y233 3/20 0.33
PLA2G2A P14555 2/20 0.33
PLA2G4A P47712 2/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PLA2G10 O15496 1/20 0.33
AHR P35869 1/20 0.33
BTK Q06187 3/20 0.32
PIK3CD O00329 2/20 0.32
PIK3CA P42336 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770664 0.96 KDM4E (0.34) KDM4ENPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL14770734 0.96 KDM4E (0.38) KDM4ENPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL14770702 0.96 KDM4E (0.38) KDM4ENPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL14770667 0.94 PLA2G2A (0.39) KDM4ENPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL10041333 0.94 KDM4E (0.38) KDM4ENPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL2628368 0.93 KDM4E (0.41) KDM4ENPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL14770662 0.92 BTK (0.38) KDM4ENPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL14770665 0.92 BTK (0.38) KDM4ENPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL14770554 0.91 KDM4E (0.36) KDM4ENPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL2628346 0.91 KDM4E (0.40) KDM4ENPC1MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604972-B2 Nitrogen-containing heteroaromatic ring compound IDEMITSU KOSAN CO., LTD. (JP) 2017-03-28 US disclosed
US-9604972-B2 Nitrogen-containing heteroaromatic ring compound IDEMITSU KOSAN CO., LTD. (JP) 2017-03-28 US disclosed
US-20130062597-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2013-03-14 US disclosed
US-20130062597-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130062597-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND TDO2, AHR, NOC2L KDM4E 1763/4885NPC1 3134/4885MAPT 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.